Skip to main content
. 2017 Nov 1;37(44):10671–10678. doi: 10.1523/JNEUROSCI.1971-17.2017

Figure 1.

Figure 1.

Dose–response relationship following AZ10419369 administration. A, Representative time-activity curve of [11C]AZ10419369 with the partial 5-HT1BR agonist AZ10419369 (5.0 μg/kg) intravenously administrated 60 min after injection of the radioligand. B, Percentage change in CBV [ΔCBV (%)] in the occipital cortex after intravenous injection of varying doses of AZ10419369. C, Dose–response relationship of the 5-HT1BR occupancy (blue) and the positive and negative peak relative change in CBV (orange).